Skip to main content
Top
Published in: Abdominal Radiology 2/2018

01-02-2018

Surgery for pancreatic cancer: critical radiologic findings for clinical decision making

Authors: Annabelle L. Fonseca, Jason B. Fleming

Published in: Abdominal Radiology | Issue 2/2018

Login to get access

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, with an estimated 53,670 new cases diagnosed and an estimated 43,090 deaths in 2017. This high mortality rate is in part due to the small percentage of patients diagnosed with local disease, as well as the biologically aggressive nature of the disease. While only 10–20% of patients will present with surgically resectable disease, this is the only possible curative therapy. Five-year survival of resected pancreatic cancer ranges from 12 to 27%. The National Comprehensive Cancer Network (NCCN) guidelines recommend specific guidelines for imaging modalities used in the diagnosis and staging of pancreatic adenocarcinoma. Indeed, high-quality imaging is not only necessary to accurately stage the disease, but is critical for the determination of key clinical decision branch points such as the determination of surgical resectability. Identification of the lesion within the pancreas, the degree of extra-pancreatic extension, and potential involvement of surrounding vascular structures with the tumor are all findings necessary to classify patients as having resectable, borderline resectable, or with unresectable primary tumors. This article reviews imaging modalities used to evaluate the pancreatic cancer patient from the surgeon’s perspective, with particular emphasis on determination of resectability and preoperative planning, as well as imaging in the postoperative period.
Literature
2.
go back to reference Ferrone CR, Brennan MF, Gonen M, et al. (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 12(4):701–706CrossRefPubMed Ferrone CR, Brennan MF, Gonen M, et al. (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 12(4):701–706CrossRefPubMed
3.
go back to reference Katz MH, Wang H, Fleming JB, et al. (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 16(4):836–847CrossRefPubMedPubMedCentral Katz MH, Wang H, Fleming JB, et al. (2009) Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 16(4):836–847CrossRefPubMedPubMedCentral
4.
go back to reference Cameron JL, He J (2015) Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 220(4):530–536CrossRefPubMed Cameron JL, He J (2015) Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 220(4):530–536CrossRefPubMed
6.
go back to reference Saftoiu A, Vilmann P (2009) Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. J Clin Ultrasound. 37(1):1–17CrossRefPubMed Saftoiu A, Vilmann P (2009) Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. J Clin Ultrasound. 37(1):1–17CrossRefPubMed
7.
go back to reference Akita H, Takahashi H, Ohigashi H, et al. (2017) FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncol. 43(6):1061–1067CrossRefPubMed Akita H, Takahashi H, Ohigashi H, et al. (2017) FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Eur J Surg Oncol. 43(6):1061–1067CrossRefPubMed
8.
go back to reference Asagi A, Ohta K, Nasu J, et al. (2013) Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas. 42(1):11–19CrossRefPubMed Asagi A, Ohta K, Nasu J, et al. (2013) Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence. Pancreas. 42(1):11–19CrossRefPubMed
9.
go back to reference Denbo JW, Fleming JB (2016) Definition and management of borderline resectable pancreatic cancer. Surg Clin North Am. 96(6):1337–1350CrossRefPubMed Denbo JW, Fleming JB (2016) Definition and management of borderline resectable pancreatic cancer. Surg Clin North Am. 96(6):1337–1350CrossRefPubMed
10.
go back to reference Tzeng CW, Fleming JB, Lee JE, et al. (2012) Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 19(6):2045–2053CrossRefPubMed Tzeng CW, Fleming JB, Lee JE, et al. (2012) Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy. Ann Surg Oncol. 19(6):2045–2053CrossRefPubMed
11.
go back to reference Low G, Panu A, Millo N, Leen E (2011) Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics. 31(4):993–1015CrossRefPubMed Low G, Panu A, Millo N, Leen E (2011) Multimodality imaging of neoplastic and nonneoplastic solid lesions of the pancreas. Radiographics. 31(4):993–1015CrossRefPubMed
12.
go back to reference Brennan DD, Zamboni GA, Raptopoulos VD, Kruskal JB (2007) Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics. 27(6):1653–1666CrossRefPubMed Brennan DD, Zamboni GA, Raptopoulos VD, Kruskal JB (2007) Comprehensive preoperative assessment of pancreatic adenocarcinoma with 64-section volumetric CT. Radiographics. 27(6):1653–1666CrossRefPubMed
13.
go back to reference Mehta VK, Fisher G, Ford JA, et al. (2001) Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 5(1):27–35CrossRefPubMed Mehta VK, Fisher G, Ford JA, et al. (2001) Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg. 5(1):27–35CrossRefPubMed
14.
go back to reference Katz MH, Marsh R, Herman JM, et al. (2013) Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 20(8):2787–2795CrossRefPubMedPubMedCentral Katz MH, Marsh R, Herman JM, et al. (2013) Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 20(8):2787–2795CrossRefPubMedPubMedCentral
15.
go back to reference Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 13(8):1035–1046CrossRefPubMed Varadhachary GR, Tamm EP, Abbruzzese JL, et al. (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 13(8):1035–1046CrossRefPubMed
16.
go back to reference Callery MP, Chang KJ, Fishman EK, et al. (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 16(7):1727–1733CrossRefPubMed Callery MP, Chang KJ, Fishman EK, et al. (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 16(7):1727–1733CrossRefPubMed
17.
go back to reference Mollberg N, Rahbari NN, Koch M, et al. (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 254(6):882–893CrossRefPubMed Mollberg N, Rahbari NN, Koch M, et al. (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 254(6):882–893CrossRefPubMed
18.
go back to reference Fong ZV, Alvino DML, Fernandez-Del Castillo C, et al. (2017) Reappraisal of staging laparoscopy for patients with pancreatic adenocarcinoma: a contemporary analysis of 1001 patients. Ann Surg Oncol 1:1–9 Fong ZV, Alvino DML, Fernandez-Del Castillo C, et al. (2017) Reappraisal of staging laparoscopy for patients with pancreatic adenocarcinoma: a contemporary analysis of 1001 patients. Ann Surg Oncol 1:1–9
19.
go back to reference Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr (2006) The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol. 17(2):189–199CrossRefPubMed Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr (2006) The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol. 17(2):189–199CrossRefPubMed
20.
go back to reference Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135(4):409–14; discussion 14–5. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGrath D, Fernandez-del Castillo C. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg. 2000;135(4):409–14; discussion 14–5.
21.
go back to reference Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014;146(1):291–304 e1. Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology. 2014;146(1):291–304 e1.
22.
go back to reference Brook OR, Brook A, Vollmer CM, et al. (2015) Structured reporting of multiphasic CT for pancreatic cancer: potential effect on staging and surgical planning. Radiology. 274(2):464–472CrossRefPubMed Brook OR, Brook A, Vollmer CM, et al. (2015) Structured reporting of multiphasic CT for pancreatic cancer: potential effect on staging and surgical planning. Radiology. 274(2):464–472CrossRefPubMed
23.
go back to reference Larson DB, Towbin AJ, Pryor RM, Donnelly LF (2013) Improving consistency in radiology reporting through the use of department-wide standardized structured reporting. Radiology. 267(1):240–250CrossRefPubMed Larson DB, Towbin AJ, Pryor RM, Donnelly LF (2013) Improving consistency in radiology reporting through the use of department-wide standardized structured reporting. Radiology. 267(1):240–250CrossRefPubMed
24.
go back to reference Plumb AA, Grieve FM, Khan SH. Survey of hospital clinicians’ preferences regarding the format of radiology reports. Clin Radiol. 2009;64(4):386–94; 95–6. Plumb AA, Grieve FM, Khan SH. Survey of hospital clinicians’ preferences regarding the format of radiology reports. Clin Radiol. 2009;64(4):386–94; 95–6.
25.
go back to reference Abrams RA, Lowy AM, O’Reilly EM, et al. (2009) Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 16(7):1751–1756CrossRefPubMed Abrams RA, Lowy AM, O’Reilly EM, et al. (2009) Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 16(7):1751–1756CrossRefPubMed
26.
go back to reference de Geus SW, Evans DB, Bliss LA, et al. (2016) Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: a Markov decision analysis. Eur J Surg Oncol. 42(10):1552–1560CrossRefPubMed de Geus SW, Evans DB, Bliss LA, et al. (2016) Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: a Markov decision analysis. Eur J Surg Oncol. 42(10):1552–1560CrossRefPubMed
27.
go back to reference Katz MH, Fleming JB, Bhosale P, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 118(23):5749–5756CrossRefPubMed Katz MH, Fleming JB, Bhosale P, et al. (2012) Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 118(23):5749–5756CrossRefPubMed
28.
go back to reference Katz MH, Merchant NB, Brower S, et al. (2011) Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 18(2):337–344CrossRefPubMed Katz MH, Merchant NB, Brower S, et al. (2011) Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 18(2):337–344CrossRefPubMed
29.
go back to reference Zhou Y, Zhang Z, Liu Y, Li B, Xu D (2012) Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 36(4):884–891CrossRefPubMed Zhou Y, Zhang Z, Liu Y, Li B, Xu D (2012) Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 36(4):884–891CrossRefPubMed
30.
go back to reference Dohan A, Eveno C, Dautry R, et al. (2015) Role and effectiveness of percutaneous arterial embolization in hemodynamically unstable patients with ruptured splanchnic artery pseudoaneurysms. Cardiovasc Intervent Radiol. 38(4):862–870CrossRefPubMed Dohan A, Eveno C, Dautry R, et al. (2015) Role and effectiveness of percutaneous arterial embolization in hemodynamically unstable patients with ruptured splanchnic artery pseudoaneurysms. Cardiovasc Intervent Radiol. 38(4):862–870CrossRefPubMed
31.
go back to reference Welsch T, Eisele H, Zschabitz S, et al. (2011) Critical appraisal of the International Study Group of Pancreatic Surgery (ISGPS) consensus definition of postoperative hemorrhage after pancreatoduodenectomy. Langenbecks Arch Surg. 396(6):783–791CrossRefPubMed Welsch T, Eisele H, Zschabitz S, et al. (2011) Critical appraisal of the International Study Group of Pancreatic Surgery (ISGPS) consensus definition of postoperative hemorrhage after pancreatoduodenectomy. Langenbecks Arch Surg. 396(6):783–791CrossRefPubMed
32.
go back to reference Zhou TY, Sun JH, Zhang YL, Zhou GH, Nie CH, Zhu TY, et al. Post-pancreaticoduodenectomy hemorrhage: DSA diagnosis and endovascular treatment. Oncotarget. 2017. Zhou TY, Sun JH, Zhang YL, Zhou GH, Nie CH, Zhu TY, et al. Post-pancreaticoduodenectomy hemorrhage: DSA diagnosis and endovascular treatment. Oncotarget. 2017.
33.
go back to reference Mise Y, Day RW, Vauthey JN, Brudvik KW, Schwarz L, Prakash L, et al. After Pancreatectomy, the “90 Days from Surgery” Definition Is Superior to the “30 Days from Discharge” Definition for Capture of Clinically Relevant Readmissions. J Gastrointest Surg. 2016;20(1):77–84; discussion Mise Y, Day RW, Vauthey JN, Brudvik KW, Schwarz L, Prakash L, et al. After Pancreatectomy, the “90 Days from Surgery” Definition Is Superior to the “30 Days from Discharge” Definition for Capture of Clinically Relevant Readmissions. J Gastrointest Surg. 2016;20(1):77–84; discussion
34.
go back to reference Smoot RL, Christein JD, Farnell MB (2006) Durability of portal venous reconstruction following resection during pancreaticoduodenectomy. J Gastrointest Surg. 10(10):1371–1375CrossRefPubMed Smoot RL, Christein JD, Farnell MB (2006) Durability of portal venous reconstruction following resection during pancreaticoduodenectomy. J Gastrointest Surg. 10(10):1371–1375CrossRefPubMed
35.
go back to reference Zyromski NJ, Howard TJ (2008) Acute superior mesenteric-portal vein thrombosis after pancreaticoduodenectomy: treatment by operative thrombectomy. Surgery. 143(4):566–567CrossRefPubMed Zyromski NJ, Howard TJ (2008) Acute superior mesenteric-portal vein thrombosis after pancreaticoduodenectomy: treatment by operative thrombectomy. Surgery. 143(4):566–567CrossRefPubMed
36.
go back to reference Witkowski ER, Smith JK, Ragulin-Coyne E, et al. (2012) Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg. 16(1):121–128CrossRefPubMed Witkowski ER, Smith JK, Ragulin-Coyne E, et al. (2012) Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg. 16(1):121–128CrossRefPubMed
37.
go back to reference Tzeng CW, Fleming JB, Lee JE, et al. (2012) Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 14(6):365–372CrossRefPubMedPubMedCentral Tzeng CW, Fleming JB, Lee JE, et al. (2012) Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 14(6):365–372CrossRefPubMedPubMedCentral
38.
go back to reference Tzeng CW, Abbott DE, Cantor SB, et al. (2013) Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 20(7):2197–2203CrossRefPubMed Tzeng CW, Abbott DE, Cantor SB, et al. (2013) Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol. 20(7):2197–2203CrossRefPubMed
Metadata
Title
Surgery for pancreatic cancer: critical radiologic findings for clinical decision making
Authors
Annabelle L. Fonseca
Jason B. Fleming
Publication date
01-02-2018
Publisher
Springer US
Published in
Abdominal Radiology / Issue 2/2018
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-017-1332-z

Other articles of this Issue 2/2018

Abdominal Radiology 2/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.